schizophrenia
Vitamin D deficiency may cause cognitive decline through weakening brain’s scaffolding
February 26, 2019Manufacturing and Production NPP, mental health, neurology, neuroscience, schizophrenia, vitamin d
Vitamin D deficiency may weaken supportive ‘scaffolding’ in the brain thus causing neurons difficulty in maintaining connections, according to a …
Cambridgeshire and Peterborough NHS Foundation Trust launches mental health clinical trials
February 4, 2019Sales and Marketing UK, clinical trials, clozapine, mental health, schizophrenia
The Cambridgeshire and Peterborough NHS Foundation Trust’s Windsor Research Unit is offering patients the chance to participate in clinical trials …
Commonly used heart and diabetes drugs may improve mental health, study finds
January 10, 2019Research and Development UCL, bipolar, mental health, research, schizophrenia
Commonly used anti-cholesterol drugs, blood pressure drugs and medicines used for diabetes may improve the mental health of those with …
Otsuka scores EU schizophrenia approval, but acute myeloid leukaemia drug flops at Phase 3
August 1, 2018Research and Development, Sales and Marketing Astex, Otsuka, Rxulti, guadecitabine, pharma, schizophrenia
It’s bittersweet news for Otsuka as it emerges that the European Commission saw fit to approve its therapy Rxulti (brexpiprazole) …
AstraZeneca jettisons schizophrenia drug for $538 million
May 8, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Luye Pharma, Seroquel, pharma, schizophrenia
AstraZeneca has confirmed it has signed a deal to jettison its schizophrenia drug Seroquel and its extended release version Seroquel …
Avatar therapy holds potential as adjunct therapy for schizophrenia
November 24, 2017Medical Communications biotech, drugs, pharma, pharmaceutical, schizophrenia
Experts have developed a new form of therapy for patients living with schizophrenia, by allowing those individuals to speak to …
Janssen says its Trevicta gets European regulatory approval as maintenance therapy for Schizophrenia
June 2, 2016Medical Communications, Research and Development European Commission, Janssen, Trevicta, schizophrenia
Janssen said the European Commission has approved its Trevicta (paliperidone palmitate, a 3‑monthly injection) as maintenance treatment of schizophrenia. Trevicta …
Heptares announces positive early-stage dementia trial results
February 10, 2016Research and Development Alzheimer's, Alzheimers, Heptares, dementia, schizophrenia
Heptares has announced positive findings from its Phase 1b clinical study with its investigational drug HTL9936 as a treatment for …
FDA approves Alkermes schizophrenia treatment
October 6, 2015Research and Development Alkermes, Aristada, FDA, schizophrenia
The US Food and Drug Administration (FDA) has approved Alkermes’s Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. Aristada …
FDA approves Lundbeck and Otsuka’s Rexulti for depression
July 14, 2015Sales and Marketing FDA, Lundbeck, Otsuka, Rexulti, US, brexpiprazole, depression, major depressive disorder, schizophrenia
Lundbeck and Otsuka have gained a yes vote from the FDA for their jointly-marketed antidepressant, Rexulti. The US regulator approved …
FDA accepts new schizophrenia drug filing
September 24, 2014Sales and Marketing FDA, Lundbeck, Otsuka, brexpiprazole, depression, schizophrenia
The FDA is reviewing Otsuka and Lundbeck’s brexpiprazole for the treatment of schizophrenia and as an adjunctive therapy for the …
Alkermes schizophrenia drug shines in Phase III
April 8, 2014Medical Communications, Research and Development, Sales and Marketing Abilify, Alkermes, aripiprazole, schizophrenia
Alkermes’ investigational schizophrenia drug has met its primary endpoint in a pivotal trial, leading the firm to seek regulatory approval …
Roche schizophrenia drug fails
January 21, 2014Research and Development, Sales and Marketing Roche, biopertin, schizophrenia
Roche’s investigational schizophrenia drug bitopertin has failed to help patients with the disorder’s negative symptoms when pitted against placebo. Two …
GMP certification bodes well for Alexza’s lead product
August 28, 2012Manufacturing and Production Alexza, FDA, GMP, schizophrenia
US drugmaker Alexza Pharmaceuticals’ manufacturing facility for lead product Adasuve has been given a green light from the Spanish medicine …
Janssen’s monthly antipsychotic approved in Europe
March 9, 2011Sales and Marketing Janssen, Xeplion, antipsychotic, injectible antipsychotic, paliperidone palmitate, schizophrenia
Janssen’s injectable antipsychotic Xeplion has been approved by the European Commission for the treatment of schizophrenia. There is no cure …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
